Firebrick Pharma Limited (FRE) is a pharmaceutical developer dedicated to advancing and commercialising innovative formulations and applications of povidone-iodine. Following over a decade of research and development, which included multiple human clinical trials, Firebrick is preparing to launch its first product, Nasodine Nasal Spray, in selected countries by 2024.